Mike Nelson

Mike is the corporate head of Cooley’s Denver office and a partner in Cooley’s Boston office. He focuses on advising emerging and growth-stage life sciences and deep tech companies, as well as the funds that invest in them, on matters relating to corporate finance, corporate governance, licensing and other intellectual property-based transactions, M&A, and public offerings.

Mike’s representative matters include new deals for:

• Inscripta
• Strand Therapeutics
• TPG Life Sciences Innovations
• Superluminal Medicines

Publications

• Co-author, “A Modeling Study of T-Type Ca2+ Channel Gating and Modulation by L-Cysteine in Rat Nociceptors,” Biophysical Journal 98: 197 – 206, 2010
• Co-author, “Molecular Mechanisms of Subtype-Specific Inhibition of Neuronal T-Type Calcium Channels by Ascorbate,” Journal of Neuroscience 27: 12577 – 1258, 2007
• Co-author, “Reducing Agents Sensitize C-Type Nociceptors by Relieving High-Affinity Zinc Inhibition of T-Type Calcium Channels,” Journal of Neuroscience 27: 8250 – 8260, 2007
• Co-author, “Is There a Role for T-Type Calcium Channels in Peripheral and Central Pain Sensitization?” Molecular Neurobiology 34: 243 – 248, 2006
• Co-author, “The Role of T-Type Calcium Channels in Epilepsy and Pain,” Current Pharmaceutical Design 12: 2189 – 2197, 2006
• Co-author, “The Endogenous Redox Agent L-Cysteine Induces T-Type Ca2+ Channel-Dependent Sensitization of a Novel Subpopulation of Rat Peripheral Nociceptors,” Journal of Neuroscience 25: 8766 – 8775, 2005